Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.32 |
| ▸ | Q9HBH1 | 1/20 | 0.32 | |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649430 | 0.95 | SSTR3 (0.36) | SSTR3FURINFOLH1SIRT2SIRT1 | |
| SCHEMBL29649549 | 0.93 | SSTR3 (0.42) | SSTR3HTR2AFOLH1SIRT2SIRT1 | |
| SCHEMBL26015675 | 0.89 | HTR2A (0.40) | SSTR3FURINHTR2AFOLH1SIRT2 | |
| SCHEMBL25377303 | 0.86 | FOLH1 (0.34) | SSTR3FURINFOLH1PDF | |
| SCHEMBL29649584 | 0.86 | FOLH1 (0.40) | SSTR3FOLH1 | |
| SCHEMBL25383060 | 0.86 | FURIN (0.37) | FURINFOLH1SIRT2SIRT1SIRT5 | |
| SCHEMBL29048536 | 0.86 | FURIN (0.37) | FURINFOLH1SIRT2SIRT1SIRT5 | |
| SCHEMBL25361536 | 0.86 | SIRT5 (0.38) | FURINFOLH1SIRT2SIRT1SIRT5 | |
| SCHEMBL25361554 | 0.86 | SIRT5 (0.38) | FURINFOLH1SIRT2SIRT1SIRT5 | |
| SCHEMBL17490581 | 0.85 | HTR2A (0.39) | SSTR3FURINHTR2AFOLH1PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957760-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | ELUCIDA ONCOLOGY, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4275758-A2 | METHODS OF FUNCTIONALIZING NANOPARTICLES | Elucida Oncology, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4257156-A2 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4103236-B1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4106820-B1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | ELUCIDA ONCOLOGY INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230021059-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | ELUCIDA ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-4106820-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | Elucida Oncology, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4103236-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2022-12-01 | — | — | US | disclosed |
| WO-2022093794-A9 | METHODS OF FUNCTIONALIZING NANOPARTICLES | ELUCIDA ONCOLOGY, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022093793-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093794-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | SSTR3 1520/4885FURIN 2202/4885HTR2A 2703/4885 |
| US-11957760-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | FOLR1, FOLR2, DHFR | SSTR3 1520/4885FURIN 2202/4885HTR2A 2703/4885 |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | SSTR3 1520/4885FURIN 2202/4885HTR2A 2703/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | SSTR3 3591/4885FURIN 2087/4885HTR2A 4236/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | SSTR3 1520/4885FURIN 2202/4885HTR2A 2703/4885 |
| US-20230021059-A1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | NDC1, NCL, CD47 | SSTR3 4332/4885FURIN 1409/4885HTR2A 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.